Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Novartis
SWOG Cancer Research Network
Medical College of Wisconsin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Ascentage Pharma Group Inc.
Masaryk University
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
Niguarda Hospital
Cancer Trials Ireland